A Phase 2 Randomized Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCC - LIVIGNO-1

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Locally Advanced Or Metastatic Hepatocellular Carcinoma (hcc)
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Locally advanced or metastatic and/or unresectable HCC with diagnosis confirmed by histology or cytology
    2. Disease that is not amenable to surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies
    3. No history of malignancy other than HCC within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death

You may not be eligible for this study if the following are true:

    1. Fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma/HCC
    2. Received in 1L an approved tyrosine kinase inhibitor (for example sorafenib or lenvatinib)
    3. Prior allogeneic stem cell or solid organ transplantation



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.